1.92
전일 마감가:
$1.86
열려 있는:
$1.89
하루 거래량:
47,625
Relative Volume:
0.18
시가총액:
$39.91M
수익:
$264.74M
순이익/손실:
$-49.71M
주가수익비율:
-0.4688
EPS:
-4.0959
순현금흐름:
$-43.55M
1주 성능:
-3.03%
1개월 성능:
-17.24%
6개월 성능:
-75.42%
1년 성능:
+117.19%
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
명칭
Camp 4 Therapeutics Corp
전화
617-651-8867
주소
ONE KENDALL SQUARE, CAMBRIDGE, CA
CAMP을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CAMP
Camp 4 Therapeutics Corp
|
1.92 | 39.91M | 264.74M | -49.71M | -43.55M | -4.0959 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-27 | 개시 | Wedbush | Outperform |
2024-11-05 | 개시 | JP Morgan | Overweight |
2024-11-05 | 개시 | Piper Sandler | Overweight |
2024-11-05 | 개시 | William Blair | Outperform |
2022-08-16 | 업그레이드 | Craig Hallum | Hold → Buy |
2021-12-22 | 다운그레이드 | Craig Hallum | Buy → Hold |
2021-09-24 | 재확인 | Craig Hallum | Buy |
2021-06-25 | 재확인 | Craig Hallum | Buy |
2020-12-18 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2020-04-17 | 업그레이드 | Jefferies | Hold → Buy |
2020-03-05 | 재확인 | Craig Hallum | Buy |
2019-12-20 | 재확인 | Craig Hallum | Buy |
2019-12-20 | 다운그레이드 | First Analysis Sec | Outperform → Neutral |
2019-06-28 | 업그레이드 | Northland Capital | Market Perform → Outperform |
2019-05-29 | 다운그레이드 | Goldman | Neutral → Sell |
2019-05-01 | 재확인 | Craig Hallum | Buy |
2019-03-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2019-01-25 | 업그레이드 | JP Morgan | Neutral → Overweight |
2018-12-21 | 업그레이드 | Craig Hallum | Hold → Buy |
2018-12-14 | 재확인 | B. Riley FBR | Buy |
2018-12-11 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
2018-12-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
2018-11-27 | 개시 | Goldman | Neutral |
2018-10-15 | 개시 | Jefferies | Hold |
2018-09-28 | 재확인 | Craig Hallum | Hold |
2018-04-27 | 재확인 | Craig Hallum | Hold |
2018-03-08 | 다운그레이드 | Craig Hallum | Buy → Hold |
2018-02-16 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
모두보기
Camp 4 Therapeutics Corp 주식(CAMP)의 최신 뉴스
CalAmp Corp. Announces CEO Changes, Effective January 22, 2024 - marketscreener.com
CalAmp Corp. Announces the Appointment of Paul Washicko as the New Senior Vice President of Product Management - marketscreener.com
Pre-market Movers: NIVF, TRAW, KKR, AGEN... - RTTNews
CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Wedbush sets CAMP4 stock at Outperform, $8 price target - Investing.com Australia
Wedbush sets CAMP4 stock at Outperform, $8 price target By Investing.com - Investing.com UK
Wedbush Initiates CAMP4 Therapeutics at Outperform With $8 Price Target - marketscreener.com
Parent's Night Out (6 months to 23 months) - Bucks County Herald newspaper
The Call EventsMount Saint Charles Middle School Field Hockey Clinic - woonsocketcall.com
ALT5 Sigma Corporation Announces Record Date for Alyea Therapeutics Corporation Transaction - The Joplin Globe
The Manufacturers Life Insurance Company Buys 3,095 Shares of Camping World Holdings, Inc. (NYSE:CWH) - Defense World
Therapeutic horseback riding facility hosts camp night for veterans, first responders - WSBT
CAMP4 Therapeutics Unveils Promising Data at ASGCT 2025 - TipRanks
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th - The Manila Times
CAMP4 Therapeutics Reports Positive Results in SYNGAP1-Related Disorders and Urea Cycle Disorders at ASGCT Annual Meeting - Nasdaq
CAMP4 Clinical Data Shows 50% Protein Boost in Primate Brain Study | CAMP Stock News - Stock Titan
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
CAMP4 Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating - TipRanks
CAMP4 Reports First Quarter 2025 Financial Results And Corporate Highlights - marketscreener.com
CAMP4 Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - Nasdaq
CAMP4 Clinical Trials Hit Major Milestone: Q1 Earnings Show Strong Pipeline Progress in Rare Disease Treatment - Stock Titan
Prediction: Nvidia Just Received Its First Wall Street Sell Rating -- and More Will Follow After May 28 - The Globe and Mail
Northeast Ohio Parent Camp and Summer Programs Guide 2025 - Northeast Ohio Parent
Jesse Dee - UnionLeader.com
Sranan Gold Announces Positive Engagement with the Local Community, a Major Stakeholder at the Tapanahony Project in Suriname - Yahoo Finance
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
14-year-old dies by suicide at Weaverville mental health program run by owner of shuttered Trails Carolina - Asheville Watchdog
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Pre-market Movers: KTTA, SXTC, GLMD, TCMD... - RTTNews
New Ulcerative Colitis Drug PALI-2108 Outperforms Standard Treatments in Crucial Disease Models - Stock Titan
Why ThredUp Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Barrick Gold Trading Cheaper Than Industry: Time to Buy the Stock? - The Globe and Mail
Daily Times Chronicle EventsBoy Scout Troop 42 Pancake Breakfast - Homenewshere.com
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting - The Manila Times
CAMP4 Therapeutics to Present Preclinical and Phase 1 Clinical Trial Data at 28th Annual Meeting of the American Society of Gene and Cell Therapy - Nasdaq
Revolutionary RNA Therapy Shows Promise: CAMP4 Unveils First Human Trial Data at Gene Therapy Conference - Stock Titan
Global School of Chess Announces 100 Full-Scholarship Seats for New Inclusivity & Awareness Camp - Yahoo Finance
Home | Department of Parks and Recreation - City and County of Honolulu (.gov)
Machine Learning-Assisted Spectroscopy Ensures Safety of Cell Therapy | Research & Technology | Apr 2025 - Photonics Spectra
Where Will Rigetti Computing Be in 10 Years? - The Globe and Mail
Programmable Therapeutics Restore Gene Expression - Mirage News
Restoring healthy gene expression with programmable therapeutics - MIT News
10 Barrel Brewing Co. and Scout Campers Unveil Camp Coldie: The Ultimate Adventure Beer - The Globe and Mail
Explorer Finds Major Gold Structure in Ontario Camp - streetwisereports.com
Top 3 Health Care Stocks Poised for Big Gains in Q2 - NewsBreak: Local News & Alerts
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2 - Benzinga
‘We couldn’t do it without them’: Camp Able in need of volunteers for equine therapy - BigCountryHomepage.com
CalAmp : Quadro Vehicles S.A. Taps LoJack Italia for Advanced Connected Vehicle Technology and Security - MarketScreener
Manasa Pamboor holds free camp for physiotherapy, speech therapy and counseling - Daijiworld
Best Stock to Buy Right Now: Amazon vs. Home Depot - The Globe and Mail
Free Camp for Physiotherapy, Speech Therapy, and Counselling at Manasa Pamboor - Mangalorean.com
Camp 4 Therapeutics Corp (CAMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):